Literature DB >> 17429091

Sunitinib and hypothyroidism.

Pascal Wolter, Herlinde Dumez, Patrick Schöffski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17429091     DOI： 10.1056/NEJMc070327

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

Review 1.  Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

Authors:  Christian Kollmannsberger; Georg Bjarnason; Patrick Burnett; Patricia Creel; Mellar Davis; Nancy Dawson; Darren Feldman; Suzanne George; Jerome Hershman; Thomas Lechner; Amy Potter; Eric Raymond; Nathaniel Treister; Laura Wood; Shenhong Wu; Ronald Bukowski
Journal:  Oncologist       Date:  2011-04-13

Review 2.  Sunitinib toxicity management - a practical approach.

Authors:  Sandeep Sehdev
Journal:  Can Urol Assoc J       Date:  2016 Nov-Dec       Impact factor: 1.862

3.  Thyroid dysfunction in patients treated with sunitinib or sorafenib.

Authors:  Julia Clemons; Dexiang Gao; Mary Naam; Kathryn Breaker; David Garfield; Thomas W Flaig
Journal:  Clin Genitourin Cancer       Date:  2012-09-25       Impact factor: 2.872

4.  Osteonecrosis of the jaw related to sunitinib.

Authors:  Felix P Koch; Christian Walter; Torsten Hansen; Elke Jäger; Wilfried Wagner
Journal:  Oral Maxillofac Surg       Date:  2011-03

5.  Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib.

Authors:  Philipp Ivanyi; Thomas Winkler; Arnold Ganser; Christoph Reuter; Viktor Grünwald
Journal:  Dtsch Arztebl Int       Date:  2008-03-28       Impact factor: 5.594

Review 6.  Medical treatment of renal cancer: new horizons.

Authors:  Basma Greef; Tim Eisen
Journal:  Br J Cancer       Date:  2016-08-04       Impact factor: 7.640

Review 7.  Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer.

Authors:  Carmine D'Aniello; Massimiliano Berretta; Carla Cavaliere; Sabrina Rossetti; Bianca Arianna Facchini; Gelsomina Iovane; Giovanna Mollo; Mariagrazia Capasso; Chiara Della Pepa; Laura Pesce; Davide D'Errico; Carlo Buonerba; Giuseppe Di Lorenzo; Salvatore Pisconti; Ferdinando De Vita; Gaetano Facchini
Journal:  Front Oncol       Date:  2019-12-11       Impact factor: 6.244

8.  The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.

Authors:  P Wolter; C Stefan; B Decallonne; H Dumez; M Bex; P Carmeliet; P Schöffski
Journal:  Br J Cancer       Date:  2008-08-05       Impact factor: 7.640

9.  Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma.

Authors:  M Gilabert; M Provansal; M Cappiello; Y Walz; N Salem; C Tarpin; S Brunelle; J Thomassin; G Gravis
Journal:  Br J Cancer       Date:  2013-09-17       Impact factor: 7.640

10.  Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent.

Authors:  Zongru Jiang; Li Wang; Xuesong Liu; Cheng Chen; Beilei Wang; Wenliang Wang; Chen Hu; Kailin Yu; Ziping Qi; Qingwang Liu; Aoli Wang; Jing Liu; Guangchen Hong; Wenchao Wang; Qingsong Liu
Journal:  Acta Pharm Sin B       Date:  2019-10-18       Impact factor: 11.413
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.